Cystic Fibrosis: Difference between revisions
No edit summary |
No edit summary |
||
| Line 5: | Line 5: | ||
https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2044.1995.tb15115.x?sid=nlm%3Apubmed | https://associationofanaesthetists-publications.onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2044.1995.tb15115.x?sid=nlm%3Apubmed | ||
https://journals.lww.com/anesthesia-analgesia/fulltext/9900/the_changing_face_of_cystic_fibrosis__an_update.283.aspx | [https://journals.lww.com/anesthesia-analgesia/fulltext/9900/the_changing_face_of_cystic_fibrosis__an_update.283.aspx The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists] | ||
[https://onlinelibrary.wiley.com/doi/10.1111/pan.14384 Cystic fibrosis in children: A pediatric anesthesiologist’s perspective] | [https://onlinelibrary.wiley.com/doi/10.1111/pan.14384 Cystic fibrosis in children: A pediatric anesthesiologist’s perspective] | ||
Revision as of 14:07, 27 November 2023
This is a Stub Notice. This page has not been completed. You can work on this page by signing in and going to the Edit tab. Thanks for helping to make PedsAnesthesia.Net Wiki useful.
Go to the Main Page to see the Topic Outline.
Go to the Generalized Suggested Outline for information on case-specific details for each page.
Go to the Test Page for examples on how to use references in the page.
Relevant Article Depot:
The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists
Cystic fibrosis in children: A pediatric anesthesiologist’s perspective
Grasemann H, Ratjen F. Cystic Fibrosis. N Engl J Med. 2023 Nov 2;389(18):1693-1707. doi: 10.1056/NEJMra2216474. PMID: 37913507.
Stoltz DA, Meyerholz DK, Welsh MJ: Origins of cystic fibrosis lung disease. N Engl J Med 2015; 372: 351-62
Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, Mall MA: Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. Lancet Respir Med 2022; 10: 267-277
Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE: Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respir Med 2021; 9: 733-746
Lee AJ, Huffmyer JL, Thiele EL, Zeitlin PL, Chatterjee D: The Changing Face of Cystic Fibrosis: An Update for Anesthesiologists. Anesth Analg 2022
Dagenais RVE, Su VCH, Quon BS: Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review. J Clin Med 2020; 10